213 related articles for article (PubMed ID: 31937317)
1. Targeting the orphan nuclear receptor NR2F6 in T cells primes tumors for immune checkpoint therapy.
Klepsch V; Pommermayr M; Humer D; Brigo N; Hermann-Kleiter N; Baier G
Cell Commun Signal; 2020 Jan; 18(1):8. PubMed ID: 31937317
[TBL] [Abstract][Full Text] [Related]
2. Beyond CTLA-4 and PD-1: Orphan nuclear receptor NR2F6 as T cell signaling switch and emerging target in cancer immunotherapy.
Klepsch V; Hermann-Kleiter N; Baier G
Immunol Lett; 2016 Oct; 178():31-6. PubMed ID: 26992368
[TBL] [Abstract][Full Text] [Related]
3. Nuclear receptor NR2F6 inhibition potentiates responses to PD-L1/PD-1 cancer immune checkpoint blockade.
Klepsch V; Hermann-Kleiter N; Do-Dinh P; Jakic B; Offermann A; Efremova M; Sopper S; Rieder D; Krogsdam A; Gamerith G; Perner S; Tzankov A; Trajanoski Z; Wolf D; Baier G
Nat Commun; 2018 Apr; 9(1):1538. PubMed ID: 29670099
[TBL] [Abstract][Full Text] [Related]
4. Emerging Next-Generation Target for Cancer Immunotherapy Research: The Orphan Nuclear Receptor NR2F6.
Klepsch V; Siegmund K; Baier G
Cancers (Basel); 2021 May; 13(11):. PubMed ID: 34073258
[TBL] [Abstract][Full Text] [Related]
5. Synergistic Antitumor Effect on Bladder Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
Zhen S; Lu J; Chen W; Zhao L; Li X
Hum Gene Ther; 2018 Dec; 29(12):1352-1363. PubMed ID: 30457360
[TBL] [Abstract][Full Text] [Related]
6. CRISPR/Cas9-Mediated Knockout of DGK Improves Antitumor Activities of Human T Cells.
Jung IY; Kim YY; Yu HS; Lee M; Kim S; Lee J
Cancer Res; 2018 Aug; 78(16):4692-4703. PubMed ID: 29967261
[TBL] [Abstract][Full Text] [Related]
7. CRISPR-Cas9 mediated efficient PD-1 disruption on human primary T cells from cancer patients.
Su S; Hu B; Shao J; Shen B; Du J; Du Y; Zhou J; Yu L; Zhang L; Chen F; Sha H; Cheng L; Meng F; Zou Z; Huang X; Liu B
Sci Rep; 2016 Jan; 6():20070. PubMed ID: 26818188
[TBL] [Abstract][Full Text] [Related]
8. T cell checkpoint regulators in the heart.
Grabie N; Lichtman AH; Padera R
Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
[TBL] [Abstract][Full Text] [Related]
9. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
[TBL] [Abstract][Full Text] [Related]
10. CRISPR/Cas9-mediated PD-1 disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells.
Rupp LJ; Schumann K; Roybal KT; Gate RE; Ye CJ; Lim WA; Marson A
Sci Rep; 2017 Apr; 7(1):737. PubMed ID: 28389661
[TBL] [Abstract][Full Text] [Related]
11. Loss of the orphan nuclear receptor NR2F6 enhances CD8
Jakic B; Olson WJ; Siegmund K; Klepsch V; Kimpel J; Labi V; Zehn D; Baier G; Hermann-Kleiter N
Cell Death Dis; 2021 Feb; 12(2):187. PubMed ID: 33589606
[TBL] [Abstract][Full Text] [Related]
12. The Nuclear Orphan Receptor NR2F6 Is a Central Checkpoint for Cancer Immune Surveillance.
Hermann-Kleiter N; Klepsch V; Wallner S; Siegmund K; Klepsch S; Tuzlak S; Villunger A; Kaminski S; Pfeifhofer-Obermair C; Gruber T; Wolf D; Baier G
Cell Rep; 2015 Sep; 12(12):2072-85. PubMed ID: 26387951
[TBL] [Abstract][Full Text] [Related]
13. Enhanced antiviral benefit of combination therapy with anti-HBV and anti-PD1 gRNA/cas9 produces a synergistic antiviral effect in HBV infection.
Zhen S; Qiang R; Lu J; Tuo X; Yang X; Li X
Mol Immunol; 2021 Feb; 130():7-13. PubMed ID: 33340931
[TBL] [Abstract][Full Text] [Related]
14. CRISPR knock out CTLA-4 enhances the anti-tumor activity of cytotoxic T lymphocytes.
Shi L; Meng T; Zhao Z; Han J; Zhang W; Gao F; Cai J
Gene; 2017 Dec; 636():36-41. PubMed ID: 28888577
[TBL] [Abstract][Full Text] [Related]
15. Effect of CRISPR/Cas9-Mediated PD-1-Disrupted Primary Human Third-Generation CAR-T Cells Targeting EGFRvIII on In Vitro Human Glioblastoma Cell Growth.
Nakazawa T; Natsume A; Nishimura F; Morimoto T; Matsuda R; Nakamura M; Yamada S; Nakagawa I; Motoyama Y; Park YS; Tsujimura T; Wakabayashi T; Nakase H
Cells; 2020 Apr; 9(4):. PubMed ID: 32316275
[TBL] [Abstract][Full Text] [Related]
16. Orphan Nuclear Receptor NR2F6 Suppresses T Follicular Helper Cell Accumulation through Regulation of IL-21.
Olson WJ; Jakic B; Labi V; Schoeler K; Kind M; Klepsch V; Baier G; Hermann-Kleiter N
Cell Rep; 2019 Sep; 28(11):2878-2891.e5. PubMed ID: 31509749
[TBL] [Abstract][Full Text] [Related]
17. Targeting immune checkpoints in hematological malignancies.
Salik B; Smyth MJ; Nakamura K
J Hematol Oncol; 2020 Aug; 13(1):111. PubMed ID: 32787882
[TBL] [Abstract][Full Text] [Related]
18. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
[TBL] [Abstract][Full Text] [Related]
19. Blockade of LAG-3 in PD-L1-Deficient Mice Enhances Clearance of Blood Stage Malaria Independent of Humoral Responses.
Furtado R; Chorro L; Zimmerman N; Guillen E; Spaulding E; Chin SS; Daily JP; Lauvau G
Front Immunol; 2020; 11():576743. PubMed ID: 33519801
[TBL] [Abstract][Full Text] [Related]
20. HDAC6 Inhibition Alleviates CLL-Induced T-Cell Dysfunction and Enhances Immune Checkpoint Blockade Efficacy in the Eμ-TCL1 Model.
Maharaj K; Powers JJ; Mediavilla-Varela M; Achille A; Gamal W; Quayle S; Jones SS; Sahakian E; Pinilla-Ibarz J
Front Immunol; 2020; 11():590072. PubMed ID: 33329575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
